What is the role of nuclear imaging in the diagnosis of synovial sarcoma?

Updated: Mar 02, 2019
  • Author: Michael J Duh, MD; Chief Editor: Felix S Chew, MD, MBA, MEd  more...
  • Print


(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. In a study by Lisle et al, (18)F-FDG-PET-derived maximum standard uptake value (SUVmax) ranged from 1.2 to 13.0 (median, 4.35). According to the study findings, pretherapy tumor SUV(max) predicted overall survival and progression-free survival. Patients who had an SUVmax greater than 4.35 were shown to have a decreased disease-free survival and were therefore at high risk for local recurrence and metastatic disease. [15]

In a retrospective study of 212 patients (160 patients with soft-tissue sarcomas, 52 patients with osseous sarcomas), Charest et al evaluated, on the basis of fluorodeoxyglucose (FDG) avidity, the sensitivity of FDG positron emission tomography/CT (PET/CT) scanning for the detection of soft-tissue and osseous sarcomas. Among the study's results, the authors determined that FDG-PET/CT scanning had a sensitivity of 80% for synovial sarcomas. [27]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!